Irinotecan Hydrochloride Injection
Brand names: Irinotecan Hydrochloride
Category: Oncology
FDA status: To Be Discontinued · Last FDA update: Feb 24, 2026 · First posted: Feb 24, 2026 · 1 manufacturers, 2 listed presentations
As of Feb 24, 2026, the FDA lists Irinotecan Hydrochloride Injection as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02) NDC 50742-401-02 |
Ingenus Pharmaceuticals LLC | Not specified | A business decision was made to discontinue manufacture of the drug. |
| Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05) NDC 50742-402-05 |
Ingenus Pharmaceuticals LLC | Not specified | A business decision was made to discontinue manufacture of the drug. |
Related medications in shortage
Other Oncology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Irinotecan Hydrochloride Injection (FDA data as of Feb 24, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Irinotecan Hydrochloride Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/irinotecan-hydrochloride-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).